Sajeev Rajan Ezhapilli MBBS, Presenter: Nothing to Disclose

Nelli Lakis MD, Abstract Co-Author: Nothing to Disclose

Mary McGrath MD, Abstract Co-Author: Nothing to Disclose

F18- FDG PET CT helps to distinguish between benign and malignant salivary gland tumors based on metabolic activity of lesions/lymph nodes.   F18- FDG PET CT plays a vital role to accurately evaluate of the primary site for possible recurrence, lymph nodes, and distant metastases which impacts patient management.  

Neoplasm of salivary glands include metastasis as well as primary salivary gland tumors and the latter is relatively uncommon. Salivary gland tumors pose a diagnostic dilemma encountered in practice which can be resolved to a great extent by appropriate use of F18- FDG PETCT. The primary purpose of this exhibit is to identify the spectrum of salivary gland tumors and illustrate PET CT findings of diverse neoplastic salivary gland tumors such as adenocarcinoma, adenoid cystic carcinoma, acinar cell carcinoma and metastasis with histopathological correlations. In addition to high sensitivity for primary tumor as well as metastasis detection, PET-CT can detect recurrent/residual tumor, distinguish from postoperative changes and monitor therapy response. The association of high F-18 FDG uptake in high grade salivary gland tumors assists in differentiating aggressive tumors from benign tumors. Furthermore, PET CT offers detection of unsuspected lesions and metastases while imaging the whole body at a single time. 

http://abstract.rsna.org/uploads/2014/14017535/14017535_4h1e.pdf

Ezhapilli, S, Lakis, N, McGrath, M, F18-FDG PET/CT: An Indispensable Tool in Assessment of Primary Salivary Gland Neoplasms with Histopathological Correlation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14017535.html